8 Overstated
The NIH funded a $30 million trial called TACT evaluating IV EDTA chelation, which found it to be effective in preventing heart disease and heart attacks.
"And the NIH did a $30 million trial called the TACT trial where they used EDTA IV chelation. EDTA specifically removes lead, and they found that it was very actually effective in preventing heart disease and heart attacks, and yet it's not part of standard medicine." (said at 0:27:35)
The NIH-funded Trial to Assess Chelation Therapy (TACT) evaluated intravenous disodium EDTA chelation in post-myocardial infarction (MI) patients. However, characterizing the trial as showing EDTA chelation was "very effective in preventing heart disease and heart attacks" overstates the published evidence. In the initial TACT trial (2013), EDTA chelation resulted in only a modest reduction in a broad composite primary end point (hazard ratio 0.82; 95% CI, 0.69-0.99; P = .035), driven mainly by reductions in coronary revascularization procedures, while individual rates of myocardial infarction, stroke, and total mortality were not significantly reduced. The authors concluded the results were insufficient to support routine clinical use. Subsequently, the follow-up TACT2 trial (2024), conducted specifically in post-MI patients with diabetes, found that despite reducing blood lead levels, EDTA chelation produced no significant reduction in primary cardiovascular events (HR 0.93; 95% CI, 0.76-1.16; P = .53) or all-cause mortality compared to placebo.
Correctly prescribed drugs administered at the proper dose and for the correct indication are the third leading cause of death in the United States.
"we know that our healthcare system itself is the third leading cause of death through prescribed drugs given for the right reason at the right dose for the right patient, not mistakes." (said at 0:37:55)
The speaker overstates the specific contribution of properly prescribed drugs. The landmark meta-analysis on properly prescribed and administered drugs (excluding errors, overdose, and noncompliance) in US hospitals estimated approximately 106,000 fatal adverse drug reactions per year, placing them between the fourth and sixth leading cause of death in the United States (Lazarou et al., 1998). The claim that medical harm is the third leading cause of death comes from analyses examining medical errors broadly—which include administrative, diagnostic, and clinical mistakes—rather than non-error, properly prescribed drug therapy alone.
Chronic loneliness confers a health risk equivalent to smoking two packs of cigarettes per day.
"if you're lonely, it's like smoking two packs of cigarettes a day in terms of your risk." (said at 0:42:48)
The speaker overstates the magnitude of the mortality risk associated with loneliness. The widely cited benchmarking from meta-analytic literature (notably by Holt-Lunstad and colleagues) compared the risk of poor social relationships to smoking up to 15 cigarettes per day (less than one pack), not two packs (40 cigarettes) per day. Furthermore, meta-analyses focusing specifically on subjective loneliness found an odds ratio of 1.26 (a 26% increase in mortality risk), which is considerably lower than the mortality risk associated with heavy smoking (two packs per day).
- partial: Social relationships and mortality risk: a meta-analytic review. (PLoS medicine 2010) · cited 7313x in the literature
"Across 148 studies (308,849 participants), the random effects weighted average effect size was OR = 1.50 (95% CI 1.42 to 1.59), indicating a 50% increased likelihood of survival for participants with stronger social relationships." (abstract, results, passage verified)
pubmedfull study (doi) - partial: Loneliness and social isolation as risk factors for mortality: a meta-analytic review. (Perspectives on psychological science : a journal of the Association for Psychological Science 2015) · cited 5945x in the literature
"Across studies in which several possible confounds were statistically controlled for, the weighted average effect sizes were as follows: social isolation odds ratio (OR) = 1.29, loneliness OR = 1.26, and living alone OR = 1.32, corresponding to an average of 29%, 26%, and 32% increased likelihood of mortality, respectively." (abstract, results, passage verified)
pubmedfull study (doi) - context: Benchmarking Social Isolation, Loneliness, and Smoking: Challenges and Opportunities for P… (American journal of epidemiology 2023) · cited 28x in the literature
"Over the past decade, the health implications of social isolation and loneliness garnered global attention due in part to a widely cited meta-analysis that benchmarked associations between cigarette smoking and mortality with associations between several social-relationship measures and mortality. Leaders in health systems, research, government, and popular media have since claimed that the harms of social isolation and loneliness are comparable to that of cigarette smoking. Our commentary examines the basis of this comparison. We suggest that comparisons between social isolation, loneliness, and smoking have been helpful for raising awareness of robust evidence linking social relationships and health. However, the analogy often oversimplifies the evidence..." (abstract, passage verified)
pubmedfull study (doi)
Having type 2 diabetes makes a person's risk of developing dementia four times higher.
"For example, your risk of dementia is four times higher if you have type 2 diabetes." (said at 1:02:02)
Type 2 diabetes is a well-established risk factor for cognitive decline and dementia, but the magnitude of risk increase is substantially smaller than claimed. Systematic reviews and meta-analyses of prospective cohort studies show that individuals with diabetes have approximately a 1.4- to 1.7-fold higher risk (a 40% to 73% relative increase) of developing all-cause dementia compared to those without diabetes (with relative risks around 1.39 for Alzheimer's disease and 2.38 for vascular dementia), well below the claimed fourfold (400%) increase.
Insulin resistance is an underlying driver of common cancers, including breast, pancreatic, ovarian, and colon cancer.
"Your risk of cancer is—many of the most common cancers: breast, pancreatic, ovarian cancer, colon cancer, pancreatic cancer. These are diseases of insulin resistance." (said at 1:02:10)
Epidemiological cohorts and meta-analyses demonstrate that insulin resistance and associated hyperinsulinemia are significant risk factors and potential tumor promoters for several malignancies, particularly pancreatic, colorectal, and postmenopausal breast cancers (typically associated with relative risks between 1.1 and 2.5). However, describing these cancers categorically as "diseases of insulin resistance" overstates the relationship. Cancer is a multifactorial disease driven primarily by somatic genetic and epigenetic alterations, and for certain cancers mentioned (such as ovarian cancer), large cohort studies demonstrate little to no direct mediating effect of insulin resistance.
- supports: Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. (Archives of physiology and biochemistry 2008) · cited 340x in the literature
"The meta-analyses showed excess risks of colorectal and pancreatic cancers associated with higher levels of circulating C-peptide/insulin and with markers of glycaemia." (abstract, results, passage verified)
pubmedfull study (doi) - partial: The triglyceride-glucose index as a measure of insulin resistance and risk of obesity-rela… (International journal of epidemiology 2020) · cited 171x in the literature
"Substantial proportions of the effect of BMI were mediated by TyG index for cancers of the pancreas (42%), rectum (34%) and colon (20%); smaller proportions for kidney (15%) and liver (11%). Little or no mediation was observed for breast (postmenopausal), endometrial and ovarian cancer." (abstract, results, passage verified)
pubmedfull study (doi) - context: Insulin resistance and cancer: molecular links and clinical perspectives. (Molecular and cellular biochemistry 2025) · cited 24x in the literature
"Studies indicate that individuals with T2DM have a 10-20% increased risk of developing various solid tumors, including colorectal, breast, pancreatic, and liver cancers. The relative risk (RR) varies depending on cancer type, with pancreatic and liver cancers showing a particularly strong association (RR 2.0-2.5), while colorectal and breast cancers demonstrate a moderate increase (RR 1.2-1.5)." (abstract, results, passage verified)
pubmedfull study (doi)
Clinical studies using ketogenic diets in stage 4 pancreatic cancer patients have demonstrated cancer remissions.
"They're doing, you know, studies of stage 4 pancreatic cancer using ketogenic diets and seeing remissions in some of these patients, which is almost like heresy in medicine." (said at 1:02:40)
Clinical studies investigating ketogenic diets alongside standard chemotherapy in metastatic (stage 4) pancreatic ductal adenocarcinoma have shown feasibility, safety, and preliminary signals toward improved progression-free survival (PFS) or stable disease, but have not demonstrated cancer remissions (cures or complete tumor eradication). In a randomized phase II screening trial of 32 patients with metastatic pancreatic cancer receiving chemotherapy (gemcitabine, nab-paclitaxel, cisplatin) with or without a medically supervised ketogenic diet (MSKD), median PFS was 8.5 months with MSKD versus 6.2 months without MSKD (HR 0.53, p = .096), and overall survival was 13.7 versus 10.2 months (HR 0.58, p = .107), representing disease stabilization and modest survival trends rather than remissions. Describing these early-phase findings as "seeing remissions in some of these patients" overstates the clinical outcomes observed.
- context: Postoperative recurrence of pancreatic cancer controlled for 9 months solely by severe car… (Clinical journal of gastroenterology 2025) · cited 1x in the literature
"After 9 months of the ketogenic diet, CT revealed stable disease. A ketogenic diet may have the therapeutic effect of suppressing tumor progression if strictly applied." (abstract, results, passage verified)
pubmedfull study (doi) - context: A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a me… (Cancer 2026) · cited 4x in the literature
"In the MSKD arm, 15 of 16 patients achieved nutritional ketosis; the median proportion of days in ketosis was 39.4%. The median PFS was 8.5 months in MSKD patients and 6.2 months in non-MSKD patients: hazard ratio, 0.53 (95% CI, 0.21-1.37); one-sided p = .096. The median OS was 13.7 months with MSKD and 10.2 months in the non-MSKD arm: hazard ratio, 0.58 (95% CI, 0.25-1.37); one-sided p = .107)." (abstract, results, passage verified)
pubmedfull study (doi)
The International Classification of Diseases, 10th Revision (ICD-10) contains 155,000 disease categories.
"For example, the diagnostic manual for diseases is called ICD-10, the International Classification of Diseases, Volume 10 or Version 10, and there's 155,000 diseases." (said at 1:03:30)
The claim overstates the number of disease categories in ICD-10. The core International Classification of Diseases, 10th Revision (ICD-10) published by WHO contains roughly 14,000 diagnostic categories. Even the expanded U.S. clinical modification for diagnosis codes (ICD-10-CM) contains approximately 68,000 to 80,000 diagnosis codes. The figure of ~155,000 represents the total number of codes when combining both ICD-10-CM diagnosis codes and ICD-10-PCS inpatient medical/surgical procedure codes, conflating medical procedures with distinct disease categories.
- partial: The next big challenge for EPs: The transition to ICD-10-CM coding system. (ED management : the monthly update on emergency department management 2015)
"The number of codes available to providers will jump from 14,000 to 80,000 with the transition to the new coding system." (abstract, results, passage verified)
pubmed - partial: Trends in Opioid-related Inpatient Stays Shifted After the US Transitioned to ICD-10-CM Di… (Medical care 2017) · cited 99x in the literature
"In October 2015, the US transitioned diagnosis coding from International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) to ICD-10-CM, increasing from ∼14,000 to 68,000 codes." (abstract, background, passage verified)
pubmedfull study (doi)
Glyphosate exposure causes lymphoma.
"Monsanto which makes glyphosate, which causes lymphoma, and then they make the drugs to treat the lymphoma." (said at 1:09:03)
The host claims that glyphosate "causes lymphoma." Systematic reviews and meta-analyses of observational epidemiological studies have found an association between heavy exposure to glyphosate-based herbicides and an increased risk of Non-Hodgkin lymphoma (meta-relative risks ranging from 1.30 to 1.41). However, stating definitively that glyphosate causes lymphoma overstates the scientific evidence, as observational studies show statistical associations rather than established direct causation, and findings across major cohorts and systematic reviews remain debated due to potential confounding, recall bias, and unmeasured pesticide co-exposures.
- context: Systematic review and meta-analysis of glyphosate exposure and risk of lymphohematopoietic… (Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes 2016) · cited 73x in the literature
"Bias and confounding may account for observed associations. Meta-analysis is constrained by few studies and a crude exposure metric, while the overall body of literature is methodologically limited and findings are not strong or consistent. Thus, a causal relationship has not been established between glyphosate exposure and risk of any type of LHC." (abstract, results, passage verified)
pubmedfull study (doi) - partial: Exposure to glyphosate-based herbicides and risk for non-Hodgkin lymphoma: A meta-analysis… (Mutation research. Reviews in mutation research 2019) · cited 370x in the literature
"Using the highest exposure groups when available in each study, we report the overall meta-relative risk (meta-RR) of NHL in GBH-exposed individuals was increased by 41% (meta-RR = 1.41, 95% confidence interval, CI: 1.13-1.75)." (abstract, results, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.